Adcendo, a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs), has completed a second Series A extension financing, raising a total of €98m (US$106m). The additional €16m…
Denmark: Adcendo completes second Series A extension to €98m
…
…






